A dose exploration study of Favipiravir for the treatment of COVID-19 infection
Latest Information Update: 09 Mar 2020
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms TRIALS
- 09 Mar 2020 New trial record
- 02 Mar 2020 According to a Sihuan Pharmaceutical media release, the Trials study was officially initiated by the Ministry of Science and Technology in early February.
- 02 Mar 2020 According to the Sihuan Pharmaceutical media release, the Trials study is led by Beijing Chaoyang Hospital affiliated with Capital Medical University, with Professor Tong Zhaohui as the leading researcher. Another two research centers include Union Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology and Wuhan Jinyintan Hospital.